Please refer the enclosed file.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evexia Lifecare Limited's Board, at its meeting on November 14, 2025, approved the unaudited standalone and consolidated financial results for Q2 FY26 and H1 FY26, along with the limited review report from statutory auditor M.A. Shah & Co., which gave a clean (unqualified) opinion. On a standalone basis, Q2 revenue from operations fell to ₹2,502.82 lakhs from ₹2,670.91 lakhs in Q2 FY25, a decline of about 6.3%, while net profit dropped sharply to ₹31.52 lakhs from ₹69.41 lakhs (roughly 55% lower). For H1 FY26, standalone revenue was ₹4,602.54 lakhs and net profit ₹88.72 lakhs versus ₹4,713.03 lakhs and ₹110.98 lakhs in H1 FY25. Consolidated Q2 revenue was ₹2,572.69 lakhs with net profit of ₹37.19 lakhs. Operating cash flow on a standalone basis was negative at ₹(433.82) lakhs for H1 FY26, reflecting working capital outflows, while consolidated operating cash flow was also negative at ₹(519.82) lakhs.
Weak quarterly show — both revenue and profits declined meaningfully year-on-year, and the company is burning cash from operations, which is a negative signal for short-term shareholders. The clean auditor opinion removes governance concerns, but the deteriorating earnings quality and cash burn may weigh on sentiment.